Grace Therapeutics (NASDAQ: GRCE) director granted 10,000 options

Rhea-AI Filing Summary

Grace Therapeutics, Inc. director Kottayil George reported a grant of a stock option covering 10,000 shares of common stock of Grace Therapeutics. The option, with an exercise price of $3.8 per share, was awarded on January 8, 2026 and is held directly.

According to the vesting terms, 25% of the option vests on the grant date, and the remaining 75% vests in substantially equal monthly installments on the 30th day of each month until September 30, 2026, subject to George’s continued service on each vesting date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kottayil George

(Last) (First) (Middle)

C/O GRACE THERAPEUTICS, INC.

103 CARNEGIE CENTER, SUITE 300

(Street)

PRINCETON NJ 08540

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Grace Therapeutics, Inc. [ GRCE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.8	01/08/2026		A		10,000		(1)	01/08/2036	Common Stock	10,000	$0	10,000	D

Explanation of Responses:

1. 25% of this option vests on the date of grant and the remaining 75% vests in substantially equal monthly installments on the 30th day of each month until September 30, 2026, subject to the Reporting Person's continuous service as of each vesting date.

	/s/ Robert DelAversano as attorney-in-fact for George Kottayil	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Grace Therapeutics (GRCE) report in this Form 4?

The filing reports that director Kottayil George received a grant of a stock option (right to buy) for 10,000 shares of Grace Therapeutics common stock on January 8, 2026.

What are the key terms of Kottayil George’s stock option grant at Grace Therapeutics (GRCE)?

The option covers 10,000 shares of common stock at an exercise price of $3.8 per share. It is reported as held directly by the director.

How does the stock option granted to Kottayil George vest at Grace Therapeutics (GRCE)?

25% of the option vests on the grant date, and the remaining 75% vests in substantially equal monthly installments on the 30th of each month until September 30, 2026, subject to his continuous service.

What is the total number of derivative securities Kottayil George holds after this transaction?

After the reported transaction, Kottayil George beneficially owns 10,000 stock options related to Grace Therapeutics common stock.

What role does the reporting person hold at Grace Therapeutics (GRCE)?

The reporting person, Kottayil George, is identified in the filing as a director of Grace Therapeutics, Inc.